Andrew Spaventa

Andrew Spaventa, listed as chief executive, has filed trades across 2 companies (mainly through SEC (Form 4)), most often in Singular Genomics Systems, Inc. and Aspen Neuroscience, Inc. The record holds 51 filings, for trades running from 1 June 2021 to 2 November 2026.

Market trades split into 2 purchases (€46k) and 4 sales (€35k). Taken together, the purchases exceed the sales by €10k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 1 share grant and 11 option exercises.

The record was last updated on 2 November 2026 with a transaction in Aspen Neuroscience, Inc. The last purchase on record was published on 20 November 2023, which is 1,084 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.